Hyaluronidase Failure Trips Partners; Halozyme Plummets
Halozyme Therapeutics Inc. took a double hit Thursday as FDA concerns about its recombinant human hyaluronidase (rHuPH20) enzyme sidetracked programs at two partners and sent the stock into a tailspin.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST